Keyphrases
Multiple Tumors
100%
Autologous Dendritic Cells
100%
Vaccination
100%
Tumor Antigen
100%
Malignant Melanoma
100%
Phase II Trial
100%
Stable Disease
100%
HLA-A2
50%
Progressive Disease
50%
Immune Response
37%
Dendritic Cells
25%
Regulatory T Cells
25%
Immune Disease
12%
Blood Levels
12%
High Affinity
12%
Antigen-presenting Cells
12%
Clinical Benefit
12%
Survivin
12%
Immune Suppressive Cells
12%
Objective Response
12%
Tumor Lysate
12%
Rapid Disease Progression
12%
Peripheral Blood
12%
Low-dose interleukin-2
12%
CD4 T Cells
12%
Antigen-specific T Cell Response
12%
T Cells
12%
Overall Survival Time
12%
Derived Peptide
12%
Telomerase
12%
Interferon-α (IFN-α)
12%
Peptide-HLA
12%
Allogeneic
12%
Monocyte-derived Cells
12%
Long-term Survival
12%
Disease Stabilization
12%
Prolonged Survival
12%
Immunology and Microbiology
Immune Response
100%
Tumor Antigen
100%
Dendritic Cell
100%
T Cell
66%
Regulatory T Cell
66%
Vaccine Peptide
33%
Peptides
33%
Overall Survival
33%
Major Histocompatibility Complex
33%
Low Drug Dose
33%
Immunity
33%
T-Helper Cell
33%
Antigen Specificity
33%
Blood Level
33%
Antigen Presenting Cell
33%
Cell Lysate
33%
Interleukin 2
33%
Interferon
33%
P53
33%
Survival Time
33%
Medicine and Dentistry
Tumor Antigen
100%
Dendritic Cell
100%
Diseases
100%
Melanoma
100%
Progressive Disease
44%
Immune Response
33%
Regulatory T Cell
22%
Interferon
11%
Neoplasm
11%
Clinical Study
11%
Antigen Specificity
11%
Protein P53
11%
Survival Time
11%
Immunity
11%
Overall Survival
11%
T Cell
11%
T-Cell Response
11%
Telomerase
11%
Survivin
11%
Polymer
11%
Disease Exacerbation
11%
T-Helper Cell
11%
Low Drug Dose
11%
Vaccine Peptide
11%
Major Histocompatibility Complex
11%
Interleukin 2
11%
Antigen Presenting Cell
11%
Deterioration
11%